Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

¼±ÅÃÀû COX-2 ¾ïÁ¦Á¦ NS 398°ú EGF ¼ö¿ëü Â÷´ÜÁ¦ AG 1478ÀÇ º¹ÇÕÅõ¿©°¡ HeLa ¼¼Æ÷ÁÖÀÇ ¹æ»ç¼± °¨¼ö¼º¿¡ ¹ÌÄ¡´Â ¿µÇâ The Modulation of Radiosensitivity by Combined Treatment of Selective COX-2 Inhibitor, NS 398 and EGF Receptor Blocker AG 1478 in HeLa Cell Line

´ëÇѹæ»ç¼±Á¾¾çÇÐȸÁö 2005³â 23±Ç 1È£ p.51 ~ 60
¼Ò¼Ó »ó¼¼Á¤º¸
À±¼±¹Î/Youn SM ¿À¿µ±â/±èÁÖÇå/¹Ú¹ÌÀÚ/¼ºÀοÁ/°­±â¹®/ä±Ô¿µ

Abstract

¸ñ Àû: ºÐÀÚ Ç¥ÀûÀÇ ¼±ÅÃÀû ¾ïÁ¦°¡ ¹æ»ç¼± ¼¼Æ÷ »ì»ó È¿°ú¸¦ ÁõÁø½ÃÅ°´Â °ÍÀ¸·Î ¾Ë·ÁÁ® ÀÖÀ¸¹Ç·Î ¼±ÅÃÀû COX-2 ¾ïÁ¦Á¦¿Í EGF ¼ö¿ëü Â÷´ÜÁ¦¸¦ HeLa ¼¼Æ÷ÁÖ¿¡ ó¸®ÇÑ ÈÄ ¹æ»ç¼± È¿°úÀÇ »ó½ÂÀÛ¿ëÀ» ¾Ë¾Æº¸°íÀÚ ÇÏ¿´´Ù.

´ë»ó ¹× ¹æ¹ý: ÀڱðæºÎ¾Ï ¼¼Æ÷ÁÖÀÎ HeLa ¼¼Æ÷¿¡¼­ EGF ¼ö¿ëü Â÷´ÜÁ¦ AG 1478, ¼±ÅÃÀû COX-2 ¾ïÁ¦Á¦ NS 398°ú ¹æ»ç¼±À» º¹ÇÕ Åõ¿©ÇÏ¿© ¼¼Æ÷¼ºÀå ¾ïÁ¦ ºÐ¼®(cell growth inhibition assay)°ú ¼¼Æ÷»ç¸ê ºÐ¼®(apoptosis assay)À» ½ÃÇàÇÏ¿´°í, ¹æ»ç¼± °¨¼ö¼º º¯È­¸¦ »ìÆ캸±â À§ÇØ ¼¼Æ÷»ýÁ¸ ºÐ¼®(clonogenic survival assay)À» ½ÃÇàÇÏ¿´´Ù. ¹æ»ç¼± °¨¼ö¼º ÀÎÀڷδ 2 Gy¿¡¼­ÀÇ ¼¼Æ÷»ýÁ¸ºÐȹ(SF2)°ú linear-quadratic modelÀ» ÀÌ¿ëÇÑ dose enhancement ratio (DER)¸¦ »ç¿ëÇÏ¿´´Ù. ¹æ»ç¼± °¨¼ö¼º¿¡ ´ëÇÑ ÀÛ¿ë±âÀü ºÐ¼®À» À§ÇØ flow cytometry·Î ¼¼Æ÷Áֱ⠺м®(cell cycle analysis)À» ½ÃÇàÇÏ¿´°í, western blot ºÐ¼®À» ÅëÇÏ¿© bcl-2¿Í bax ´Ü¹éÁúÀÇ ¹ßÇö º¯È­¸¦ »ìÆ캸¾Ò´Ù.

°á °ú: HeLa ¼¼Æ÷¿¡ NS 398°ú AG 1478À» ¹æ»ç¼±°ú ÇÔ²² º¹ÇÕ Åõ¿©ÇÑ ½ÇÇè ±º¿¡¼­ ¼¼Æ÷»ç¸ê Á¤µµ°¡ °¡Àå ³ô°Ô ³ªÅ¸³µ´Ù(8.49% vs. 22.70%). ¼¼Æ÷Áֱ⠺м® °á°ú, ¹æ»ç¼±°ú º¹ÇÕ ¾à¹° 󸮱º¿¡¼­ G0/G1 ¼¼Æ÷ÁÖ±â Á¤Ã¼¿Í S ¼¼Æ÷ ºÐȹ ¼Ò½ÇÀÌ ³ªÅ¸³µÀ¸¸ç ÀÌ·¯ÇÑ º¯È­´Â 72½Ã°£ ÀÌÈıîÁö Áö¼ÓµÇ¾ú´Ù. ¼¼Æ÷»ýÁ¸ ºÐ¼® °á°ú·Î´Â ¹æ»ç¼±°ú AG 1478±º¿¡¼­ SF2 0.68¡¾0.07, DER 1.12¸¦ º¸ÀÎ ¹Ý¸é, ¹æ»ç¼±°ú º¹Çվ๰󸮱º¿¡¼­´Â SF2 0.12¡¾0.01, DER 3.00À¸·Î ³ªÅ¸³µ´Ù. Western blot ºÐ¼®¿¡¼­´Â ¹æ»ç¼±°ú º¹Çվ๰󸮱º¿¡¼­ bcl-2¿Í bax ´Ü¹éÁú ¹ßÇöÀÌ ¸ðµÎ °¨¼ÒÇÏ´Â ¾ç»óÀ» º¸¿´´Ù.

°á ·Ð: ½ÅÈ£Àü´Þ ü°è¸¦ ¾ïÁ¦ÇÏ´Â ºÐÀÚ Ç¥Àû ¾àÁ¦ÀÎ ¼±ÅÃÀû COX-2 ¾ïÁ¦Á¦¿Í EGF ¼ö¿ëü Â÷´ÜÁ¦¸¦ ¹æ»ç¼±°ú º¹ÇÕ Åõ¿©ÇÔÀ¸·Î½á HeLa¼¼Æ÷ÀÇ ¹æ»ç¼± °¨¼ö¼ºÀÌ Áõ°¡µÊÀ» È®ÀÎÇÏ¿´´Ù.

Purpose: Selective inhibition of multiple molecular targets may improve the antitumor activity of radiation. Two specific inhibitors of selective cyclooxygenase-2 (COX-2) and epidermal growth factor receptor (EGFR) were combined with radiation on the HeLa cell line. To investigate cooperative mechanism with selective COX-2 inhibitor and EGFR blocker, in vitro experiments were done.

Materials and Methods: Antitumor effect was obtained by growth inhibition and apoptosis analysis by annexin V-Flous method. Radiation modulation effects were determined by the clonogenic cell survival assay. Surviving fractions at 2 Gy (SF2) and dose enhancement ratio at a surviving fraction of 0.25 were evaluated. To investigate the mechanism of the modulation of radiosensitivity, the cell cycle analyses were done by flow cytometry. The bcl-2 and bax expressions were analyzed by western blot.

Results: A cooperative effect were observed on the apoptosis of the HeLa cell line when combination of the two drugs, AG 1478 and NS 398 with radiation at the lowest doses, apoptosis of 22.70% compare with combination of the one drug with radiation, apoptosis of 8.49 %. In cell cycle analysis, accumulation of cell on G0/G1 phase and decrement of S phase fraction was observed from 24 hours to 72 hours after treatment with radiation, AG 1478 and NS 398. The combination of NS 398 and AG 1478 enhanced radiosensitivity in a concentration-dependent manner in HeLa cells with dose enhancement ratios of 3.00 and SF2 of 0.12 but the combination of one drug with radiation was not enhanced radiosensitivity with dose enhancement ratios of 1.12 and SF2 of 0.68 (p=0.005). The expression levels of bcl-2 and bax were reduced when combined with AG 1478 and NS 398.

Conclusion: Our results indicate that the selective COX-2 inhibitor and EGFR blocker combined with radiation have potential additive or cooperative effects on radiation treatment and may act through various mechanisms including direct inhibition of tumor cell proliferation, suppression of tumor cell cycle progression and inhibition of anti-apoptotic proteins.

Å°¿öµå

Selective COX-2 inhibitor; EGFR blocker; Radiation; HeLa cell line; ¼±ÅÃÀû COX-2 ¾ïÁ¦Á¦; EGF ¼ö¿ëü Â÷´ÜÁ¦; ¹æ»ç¼±; HeLa ¼¼Æ÷ÁÖ

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

   

µîÀçÀú³Î Á¤º¸

KCI
KoreaMed
KAMS